Evidence map›Paper›PMID 20686604›Full record

ArticlePloS one2010

Common ADRB2 haplotypes derived from 26 polymorphic sites direct beta2-adrenergic receptor expression and regulation phenotypes.

Alfredo Panebra, Wayne C Wang, Molly M Malone, Demar R G Pitter, Scott T Weiss, Gregory A Hawkins, Stephen B Liggett

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Association of polymorphisms in the beta-2 adrenergic receptor gene with fracture risk and bone mineral density.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. βmedRxiv : the preprint server for health sciences · 2025
    Article
  6. Review
  7. CRISPR/Cas9-mediated generation and analysis of N terminus polymorphic models of βMolecular therapy. Methods & clinical development · 2021
    Article
  8. Review
  9. Article
  10. A CREB-mediated increase in miRNA let-7f during prolonged β-agonist exposure: a novel mechanism of βFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Alfredo PanebraCardiopulmonary Genomics Program, University of Maryland, Baltimore, Maryland, United States of America.
Wayne C Wang
Molly M Malone
Demar R G Pitter
Scott T Weiss
Gregory A Hawkins
Stephen B Liggett
University of Maryland, Baltimore · USHarvard University · USWake Forest University · US

Funding

THE PHARMACOGENETICS OF ASTHMA TREATMENTU01HL065899 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI TANTISIRA, KELAN G, WEISS, SCOTT T · 2000 to 2014
$38.5M
Molecular properties of B-adrenergic receptors in AsthmaR37HL045967 · NHLBI · UNIVERSITY OF SOUTH FLORIDA · PI LIGGETT, STEPHEN B · 2002 to 2012
$3.2M
MOLECULAR PROPERTIES OF B-ADRENERGIC RECEPTORS IN ASTHMAR01HL045967 · NHLBI · UNIVERSITY OF SOUTH FLORIDA · PI LIGGETT, STEPHEN B · 1990 to 2018
$1.3M
Molecular properties of B-adrenergic receptors in AsthmaR56HL045967 · NHLBI · UNIVERSITY OF SOUTH FLORIDA · PI LIGGETT, STEPHEN B · 2015 to 2015
$374k
NHLBI NIH HHS HL045967NHLBI NIH HHS HL065899NHLBI NIH HHS R01 HL045967NHLBI NIH HHS R37 HL045967NHLBI NIH HHS R56 HL045967NHLBI NIH HHS U01 HL065899
6 · The paper itself

Abstract

backgroundThe beta2-adrenergic receptor (beta2AR) is expressed on numerous cell-types including airway smooth muscle cells and cardiomyocytes. Drugs (agonists or antagonists) acting at these receptors for treatment of asthma, chronic obstructive pulmonary disease, and heart failure show substantial interindividual variability in response. The ADRB2 gene is polymorphic in noncoding and coding regions, but virtually all ADRB2 association studies have utilized the two common nonsynonymous coding SNPs, often reaching discrepant conclusions. METHODOLOGY/PRINCIPAL

findingsWe constructed the 8 common ADRB2 haplotypes derived from 26 polymorphisms in the promoter, 5'UTR, coding, and 3'UTR of the intronless ADRB2 gene. These were cloned into an expression construct lacking a vector-based promoter, so that beta2AR expression was driven by its promoter, and steady state expression could be modified by polymorphisms throughout ADRB2 within a haplotype. "Whole-gene" transfections were performed with COS-7 cells and revealed 4 haplotypes with increased cell surface beta2AR protein expression compared to the others. Agonist-promoted downregulation of beta2AR protein expression was also haplotype-dependent, and was found to be increased for 2 haplotypes. A phylogenetic tree of the haplotypes was derived and annotated by cellular phenotypes, revealing a pattern potentially driven by expression. CONCLUSIONS/SIGNIFICANCE: Thus for obstructive lung disease, the initial bronchodilator response from intermittent administration of beta-agonist may be influenced by certain beta2AR haplotypes (expression phenotypes), while other haplotypes may influence tachyphylaxis during the response to chronic therapy (downregulation phenotypes). An ideal clinical outcome of high expression and less downregulation was found for two haplotypes. Haplotypes may also affect heart failure antagonist therapy, where beta2AR increase inotropy and are anti-apoptotic. The haplotype-specific expression and regulation phenotypes found in this transfection-based system suggest that the density of genetic information in the form of these haplotypes, or haplotype-clusters with similar phenotypes can potentially provide greater discrimination of phenotype in human disease and pharmacogenomic association studies.

Indexed as

3' Untranslated Regions5' Untranslated RegionsAnimalsBlotting, WesternChlorocebus aethiopsCOS CellsHaplotypesHumansPhenotypePhylogenyPolymorphism, GeneticPromoter Regions, GeneticReceptors, Adrenergic, beta-2Reverse Transcriptase Polymerase Chain Reaction3' Untranslated Regions5' Untranslated RegionsReceptors, Adrenergic, beta-2

Identifiers

PMID20686604
PMCPMC2912278
OpenAlexW2044132424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.